Cystathionine beta synthase gene dose dependent vascular remodeling in murine model of hyperhomocysteinemia

International Journal of Physiology, Pathophysiology and Pharmacology

Volumn 3, Issue 3, 2011, Pages 210-222

  Tyagi, Neetu ^a   Qipshidze, Natia ^a   Sen, Utpal ^a   Rodriguez, Walter ^a   Ovechkin, Alexander ^a   Tyagi, Suresh C ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

Aorta stiffness; Endothelial function; Endothelin; Hypertension; Mitochondrial nitric oxide; MMP; NOX1; Peroxiredoxin; PPAR; ROS; Thioredoxin; TIMP

Indexed keywords

CYSTATHIONINE BETA SYNTHASE; HOMOCYSTEINE; MATRIX METALLOPROTEINASE; NITRIC OXIDE SYNTHASE; PEROXIREDOXIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; REACTIVE OXYGEN METABOLITE; THIOREDOXIN;

ALLELE; ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FIBROSIS; GENE DOSAGE; HOMOCYSTINURIA; HYPERHOMOCYSTEINEMIA; MALE; MORBIDITY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OXIDATIVE STRESS; PHENOTYPE; PROTEIN EXPRESSION; SMOOTH MUSCLE;

EID: 80052987097     PISSN: None     EISSN: 19448171     Source Type: Journal    
DOI: None     Document Type: Article

References (65)

1. Aléssio AC, Siqueira LH, Bydlowski SP, Höehr NF, Annichino-Bizzacchi JM. Polymorphisms in the CBS gene and homocysteine, folate and vitamin B12 levels: association with polymorphisms in the MTHFR and MTRR genes in Brazilian children. Am J Med Genet A. 2008; 146A: 2598-2602.
2. Konecky N, Malinow MR, Tunick PA, Freedberg RS, Rosenzweig BP et al., Correlation between plasma homocysteine and aortic atherosclerosis, Am Heart J, 1997; 133: 534-540.
3. Tribouillay CM Peltier M, Iannetta Peltier MC, et al., Plasma homocysteine and severity of thoracic aortic atherosclerosis, Chest, 2000; 118: 1685-1689.
4. Nygard O, Vollset SE, et al. Total plasma homocysteine and cardiovascular risk profile. J Am Med Assoc, 1995; 274: 1526-1533.
5. Malinow MR, Levenson J, et al. Role of blood pressure, uric acid and hemorheological parameters on plasma homocysteine concentration, Atherosclerosis, 1995; 114: 175-183.
6. Sutton-Tyrrell K, Bostom A, Selhub J, Ziegler- Johson C. High homocysteine levels are independently related to isolated systolic hypertension in older adults, Circulation, 1997; 96: 1745-1749.
7. Miller A, Mujumdar V, Shek E, Guillot J, Angelo M, Pakmer L, Tyagi SC. Hyperhomocysteinemia induces multiorgan damage, Heart & Vessels, 2000; 15: 135-143.
8. Rolland PH, Friggi A, Barlatier A, Piquet P, Latrille V, Faye MM, Guillou J, Charpioy P, Bodard H, Ghininghelli O, Calaf R, Luccioni R, Garcon D. Hyperhomocysteinemia-induced vascular damage in the minipigs. Circulation. 1995; 91: 1161-1174.
9. Barger PM, Brandt JM, Leone TC, Weinheimer CJ, Kelly DP. Deactivation of PPARα during cardiac hypertrophic growth, J Clin Invest, 2000; 105: 1723-1730.
10. Smiley LM, Camp TM, Lucchesi PA, Tyagi SC. Peroxisome proliferator ameliorates endocardial endothelial and muscarinic dysfunction in spontaneously hypertensive rats, Antioxidants & Redox Signaling, 2004; 6: 367-374.
11. Tyagi SC. Homocyst(e)ine and heart disease: pathophysiology of extracellular matrix, Clin Exper Hyperten, 1999; 21: 181-198.
12. Appel LJ, Moore TJ, Obarzanek E, Vollmer WM et al., A clinical trial of the effects of dietary patterns on blood pressure, N Eng J Med, 1997; 337: 637-638.
13. Evans M, Anderson RA, Graham J, Ellis GR, et al., Ciprofibrate therapy improves endothelial function and reduces postprandial lipemia and oxidative stress in type 2 diabetes mellitus, Circulation, 2000; 101: 1773-1779.
14. Mujumdar VS, Aru GM, Tyag SC. Induction of oxidative stress by homocyst(e)ine impairs endothelial function, J Cell Biochem, 2001; 82: 491-500.
15. Eberhardt RT, Forgione MA, Cap A, Leopold JA, et al., Endothelial dysfunction in a murine model of mild hyperhomocysteinemia, J Clin Invest, 2000; 106: 483-491.
16. Lentz SR, et al. Vascular dysfunction in monkeys with diet-induced hyperhomocysteinemia, J Clin Invest, 1996; 98: 24-29.
17. Tyagi SC, Smiley LM, Mujumdar VS. Homocyst (e)ine impairs endocardial endothelial function, Canad J Physiol & Pharmacology, 1999; 77: 950-957.
18. Sood HS, Hunt MJ, Tyagi SC. Peroxisome proliferator ameliorates endothelial dysfunction in a murine model of hyperhomocysteinemia, Am J Physiol 2003; 284: L333-L341.
19. Bryk R, Griffin P, Nathan C. Peroxynitrite reductase activity of bacterial peroxiredoxins. Nature. 2000 Sep 14; 407: 211-5.
20. Wong CM, Zhou Y, Ng RW, Kung Hf HF, Jin DY. Cooperation of yeast peroxiredoxins Tsa1p and Tsa2p in the cellular defense against oxidative and nitrosative stress. J Biol Chem. 2002 Feb 15; 277: 5385-94.
21. Barr SD, Gedamu L. Role of peroxidoxins in Leishmania chagasi survival. Evidence of an enzymatic defense against nitrosative stress. J Biol Chem. 2003 Mar 21; 278: 10816-23.
22. Farina AR, et al., Thioredoxin alters the MMP/ TIMP balance and stimulates human SK-N-SH neuroblastoma cell invasion, Eur J Biochem, 2001; 268: 405-413.
23. Jones TG, Hancock JT. Assay of plasma membrane NADPH oxidase, Methods Enzymol, 1994; 233: 222-2229.
24. Oh JH, et al, Thioredoxin sectreted unpon UV A irradiation modulates MMP-2 and TIMP in human dermal fibroblasts, Arch Biochem Biophys, 2004; 423: 218-226.
25. Hui TY, et al, Mice lacking thioredoxin interacting protein provide linking cellular redox state to appropriate response to nutritional signals, J Biol Chem, 2004; March 26.
26. Shao LE, et al., Thioredoxin-related regulation of NO/NOS activities, Ann N. Y. Acda Sci, 2002; 962: 140-150.
27. Berman RS, Martin W. Arterial endothelial barrier dysfunction: actions of homocysteine and the hypoxanthine-xanthine oxidase free radical generating system, Br J Pharmacol, 1993; 108: 920-906.
28. Yamamoto M, Hara H, Adachi T. Effects of homocysteine on the binding of extracellularsuperoxide dismutase to the endothelial cell surface. FEBS Lett. 2000 Dec 8; 486: 159-62.
29. Goth L, Vitai M. The effects of hydrogen peroxide promoted by homocysteine and inherited catalase deficiency on human hypocatalasemic patients. Free Radic Biol Med. 2003 Oct 15; 35: 882-888.
30. Poynter ME, Daynes RA. PPARalpha activation modulates cellular redox status, represses NFkB signaling, and reduces inflammatory cytokine production in aging, J Biol Chem, 1998; 273: 32833-32841.
31. Inoue I, Goto SS, Matsunaga T, Nakajima T, Awara T, Hokari S, Komoda T, Katayama S. The ligands/activators for PPAR alpha and gamma increase Cu-Zn SOD and decrease p22phox message expressions in primary endothelial cells. Metabolism, 2001; 50: 3-11.
32. Hunt MJ and Tyagi SC. Peroxisome proliferators compete and ameliorate homocysteinemediated endocardial endothelial cells activation, Am J Physiol, 2002; 283: C1073-C1079.
33. Watanabe M, Osada J, Aratani Y, Kluckman K, Reddick R, Malinow MR, Maeda N. Mice deficient in cystathionine β synthase:animal models for mild and severe homocysteinemia, Proc Natl Acad Sci (USA), 1995; 92: 1585-1589.
34. Nolte RT, Wisely GB, Westin S, Cobb JE, et al., Ligand binding and co-activator assembly of the PPARg, Nature, 1998; 395: 137-143.
35. Wang G, Siow YL, O, K. Homocysteine stimulates NFkB activity and monocyte chemoattractant protein-1 expression in vascular smooth muscle cells: a possible role for protein kinase C. Biochem J, 2000; 352: 817-826.
36. Papaioannou VE, Fox JG. Efficacy of tribromoethanol anesthesia in mice, Lab Anim Sci,1993; 43: 189-192.
37. Hodgkin DD, Gilbert RD, Roos PJ, Sandberg LB, Boucek RJ. Dietary lipid modulation of connective tissue matrix in rat abdominal aorta, Am J Physiol, 1992; 262: R389-R394.
38. Juge-Aubry C, Pernin A, Favez T, Burger AG, Wahli W, Meier CA, Desvergne B. DNA binding propterties of PPAR subtypes on various natural PPRE. J Biol Chem, 1997; 272: 25252-25259.
39. Sakamoto A, Sakura N. Limited effectiveness of betaine therapy for CBS deficiency. Pediatr Int., 2003; 45: 333-338.
40. Jiang X, Yang F, Tan H, Liao D, Bryan jr RM, Randhawa JK, Rumbaut RE, Durante W, Schafer AI, Yang X, Wang H. Hyperhomocysteinemia impairs endothelial function and eNOS activity via PKC activation. Arterioscler Thromb Vasc Biol, 2005; 25: 2515-21.
41. Nugent A, Hadden DR, Carson NAJ. Long-term survival of homocystinuria: the first case, The LANCET, 1998; 352: 624-625.
42. Argmann C, Dobrin R, Heikkinen S, Auburtin A, Pouilly L, Cock TA, Kautnikova H, Zhu J, Schadt EE, Auwerx J. PPAR gamma 2 is a key driver of longevity in the mouse. PLoS Genet. 2009; 5: e1000752.
43. Wang L, Chen X, Tang B, Hua X, Klein-Szanto A, Kroger WD. Expression of mutant human CBS resues neonatal lethality but not homocystinurea in a mouse model, Human Mol Genetics, 2005; 14: 2201-2208.
44. Ricote M, Huang JT, Welch JS, Glass CK. The peroxisome proliferator-activated receptor (PPAR) as a regulator of monocyte/ macrophase function, J Leukoc Biol, 1999; 66: 733-739.
45. Marx N, Sukhova G, Murphy C, Libby P, Plutzky J, Macrophages in human atheroma conain PPAR: Differential dependent peroxisomal proliferator activated receptorγ expression and reduction of MMP-9 activity through PPAR activation in mononuclear phaocytes in vitro, Am J Pathol, 1998; 153: 17-23.
46. Senior RM, Griffin GL, Eliszar CJ, Shapiro SD, Goldberg GI, and Welgus HG, Human 92- and 72- kilodalton type IV collagenases are elastases, J Biol Chem, 1991; 266: 7870-7875.
47. Martyn CN, Greenwald SE. Impaired synthesis of elastin in walls of aorta and large conduit arteries during early development as an initiating event in pathogenesis of systemic hypertension, LANCET, 1997; 350: 953-955.
48. Bushehri N, Taylor S, Lieberan S, Mirdamadi- Zonozi N, Birkmayer G, Preuss HG. Oral reduced b-nicotinamide adenine dinucleotide (NADH) affects blood pressure, lipid peroxidation, and lipid profile in hypertensive rats (SHR), Geriat Nephrol Urol, 1998; 8: 95-100.
49. Sethi AS, Lees DM, Douthwaite JA, Dawnay AB, Corder R. Homocysteine-induced endothelin- 1 release is dependent on hyperglycaemia and reactive oxygen species production in bovine aortic endothelial cells. J Vasc Res. 2006; 43(2): 175-83.
50. Fernandez-Patron C, Zouki C, Whittal R, Chan JS, Davidge ST, Filep J. MMPs regulate neutrophil- endothelial cell adhesion through generation of endothelin-1 (1-32). FASEB J, 2001; 15: 2230-2240.
51. Miura H, Liu Y, Gutterman DD. Human coronary arteriolar dilation to bradykinin depends on membrane hyperpolarization: contribution of nitric oxide and Ca2+-activated K+ channels. Circulation. 1999 Jun 22; 99: 3132-8.
52. Ludmer PL SA, Shook TL, Wayne RR, Mudge GH, Alexander RW, Ganz P. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med, 1986; 315: 1046-1051.
53. Minamikawa J, Tanaka S, Yamauchi M, Inoue D, Koshiyama H. Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes, J Clin Endocrinol Metabol, 1998; 86: 1818-1820.
54. Lake-Bruse KD, Faraci FM, Shesely EG, Maeda N, Sigmund CD, Heistad DD. Gene transfer of eNOS in eNOS-deficent mice, Am J Physiol, 1999; 277: H770-H776.
55. Mombouli JV, Vanhoutte PM. Endothelial dysfunction: from physiology to therapy. J Mol Cell Cardiol, 1999; 31: 61-74.
56. Mujumdar VS, Tummalapalli CM, Aru GM, Tyagi SC. Mechanism of constrictive vascular remodeling: a role of PPAR, Am J Physiol, 2002; 282: C1009-C1015.
57. Murthy SN, Obregon DF, Cattergoon NN, Fonseca NA, Mondal D, Dunne JB, Diez JG, Jeter JR Jr., Kadowitz PJ, Agrawal KC, McNamara DB, Fonseca VA. Rosiglitazone reduces serum Hcy levels, smooth muscle proliferation, and intimal hyperplasia in Sprague- Dawley rats fed a high methionine diet, Metabolism, 2005; 54: 645-652.
58. Inoue I, Goto S, Mizotani K, Awata T, Mastunaga T, Kawai S, Nakajima T, Hokari S, Komoda T, Katayama S. Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effect: reduction of mRNA levels for Il-1beta, Il- 6, cyclooxygenase-2, and p22phox by regulation of PPARalpha in primary endothelial cells. Life Sci, 2000; 67: 863-876.
59. Blane GF. Comparative toxicity and safety profile of fenofibrate and other fibric acid derivatives, Am J Med, 1987; 83: 26-36.
60. Dierkes J, Westphal S, Luley S. Serum homocysteine increases after therapy with fenofibrate or bezafibrate, LANCET, 1999; 354: 219-220.
61. Bissonnette R, Treacy E, Rozen R, Boucher B, Cohn JS, Genest J. Fenofibrate raises plasma homocysteine levels in the fased and fed states, Atherosclerosis, 2001; 155: 455-462.
62. Wollesen F, Brattstrom L, Refsum H, et al. Plasma total homocysteine and cysteine in relation to glomerular filteration rate in diabetes mellitus, Kidney Intern, 1999; 55: 1028-1035.
63. Tyagi N, Moshal KS, Lominadze D, Ovechkin AV, Tyagi SC. Hcy-dependent cardiac remodeling and endothelial-myocyte coupling in two kidney one clip Goldblatt hypertension mouse model. Canad J Physiol & Pharmacol, 2005; 83: 583-594.
64. Tyagi N, Sordis KC, Moshal KS, Ovechkin AV, Tyagi SC. Mechanisms of Homocysteine- Induced Oxidative Stress, Am J Physiol Heart & Circulatory Physiol, 2005; 289: H2649-56.
65. Tyagi N, Moshal KS, Ovechkin AV, Rodriguez W, Steed M, Henderson B, Roberts AM, Joshua IG, Tyagi SC.Mitochondrial mechanism of oxidative stress and systemic hypertension in hyperhomocysteinemia, J Cell Biochem, 2005; 96: 665-671.